Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Horizon Discovery Group Plc LSE:HZD London Ordinary Share GB00BK8FL363 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 184.50 184.50 185.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 58.3 -11.5 -3.1 - 291

Horizon Discovery Share Discussion Threads

Showing 1301 to 1325 of 1475 messages
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
DateSubjectAuthorDiscuss
17/4/2020
12:42
'the announcement didn't say at what price the shares would be placed' Correct - have a gander https://www.investopedia.com/terms/a/acceleratedbookbuild.asp
soundbuy
17/4/2020
12:29
Unless I missed it, the announcement didn't say at what price the shares would be placed. I always think it is rather unfair that existing ordinary shareholders, who sill suffer from some dilution, whereas I think directors can participate. I wonder if and when we will ever get our money back let alone any return on it.
bouleversee
17/4/2020
12:02
Placing ahoy.......4.5%... Hopefully taken as a positive.....but that will down to the bookbuild.....
soundbuy
14/4/2020
21:59
...Horizon is already a key supplier for research relating to COVID-19, providing many tools and services to academia and industry to support their efforts in addressing the pandemic. This offering further extends Horizon’s COVID-19 support portfolio: hxxps://horizondiscovery.com/en/products/covid19-research-support Jesús Zurdo, Global Head Bioprocessing, Horizon Discovery said: “The current coronavirus crisis is highlighting existing shortcomings in the development of much-needed therapeutics. Horizon Discovery is fully committed to help innovators in their efforts to develop new solutions to tackle the COVID-19 pandemic. We are providing immediate access to our state-of-the-art bioproduction platform under very favorable terms to facilitate such efforts.” Terry Pizzie, CEO, Horizon Discovery said: “We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.” https://uk.advfn.com/stock-market/london/horizon-discovery-HZD/share-news/Horizon-Discovery-Offers-CHOSOURCE-Platform-For-C/82223440
rambutan2
14/4/2020
14:51
Https://finance.yahoo.com/news/horizon-discovery-offers-chosource-platform-132100623.html
jaws6
12/4/2020
10:41
Https://horizondiscovery.com/products/covid19-research-support
carpingtris
12/4/2020
10:35
Https://www.businessweekly.co.uk/news/biomedtech/horizon-discovery-boosts-armoury-821bn-cell-market Https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/horizon-discovery-pharmahungary-report-positive-140900876.html
carpingtris
12/4/2020
09:26
Love the optimism, but can someone explain how HZD reagents can be applied to Covid19. Maybe therapeutics - identifying key genes involved - but not IVD testing. The co update didnt sound like this is a Covid19 slam dunk
kestelmill
12/4/2020
09:04
Thanks. From what I've read, a shortage of reagents is one of the main barriers to effective testing for Covid-19. So maybe there is an angle for HZD here. The press article refers to a Cambridge-based company in addition to the two majors.
mamcw
12/4/2020
08:39
From the HZD website, dated 3 April: “In terms of Covid-related activity it’s a very different take: we are engaging with some institutions in the US and we may be able to provide reagents to them. Of course, we don’t always know if they’re testing for Covid-19 but there are various institutions and government bodies where we can be of use.” AstraZeneca is of course "a Cambridge based company".
bobdouthwaite
12/4/2020
08:27
According to Alliance news, GSK, AstraZeneca and a Cambridge based company are working together to deliver a validated Covid-19 antibody test by the beginning of May. Anyone know if this Cambridge-based company is by chance HZD, as it has good links with both of these majors?
mamcw
07/4/2020
06:43
Woodford is due to make a come back soon Clever money is buying his old favourites 'Criminals always return to the scene of their crimes'
the stigologist
07/4/2020
06:10
Any selling now won't be from Woodford, he was out last year. Confirmed by CEO during HY 2019 webcast presentation Q&A made in September 2019.
edwards9
06/4/2020
13:04
It might be of interest to recall that in 2017 Woodford and Invesco (Perpetual) held an aggregate of 33% of HZD stock at the peak. Most of the Woodford stake was taken by Value Act (20.9% holder). The company website shows neither are now significant (that os over 3%) holders. Bottom of the list at #9 is the new shareholder Platinum at 3% (4.5mn shares of the 150mn in issue). I wanted to check this as I see the Perpetual Income & Growth Trust Trust is seeking a new manager after a pretty dire performance under Perpetual management over the past five years. Danaher is the third largest after Value Act and Canaccord.
srichardson8
04/4/2020
19:29
There was exceptionally large volume in HXD yesterday, over 1mn shares, mostly in a few block trades 'off market'. One could speculate that this may be further selling from the rump of the Neil Woodford holding, or possibly from his former acolyte at Invesco who was already under redemption pressure prior to the general market collapse. I suppose the point, in the short term anyway, is that another institution is prepared to pick up a reasonably large size line at around the current price and this is mildly encouraging. Over the past three months Horizon has pretty much behaved in line with the market, no better no worse. The most recent company statement outlined the delay to publication of the annual figuers (to Dec 2019)and suggested that the company is still able to trade in the current climate and has an 'OK'cash position. Personally I have kept my position intact as I still believe that it is well-positioned as a supplier to the gene editing market but I accept that it is a pretty high risk investment. The stock market is hugely volatile and highly unpredictable at the moment. None of us have seen the like. 'Experts' have been giving advice freely but we are all basically hoping that there is some breakthrough on the c-19 front before long and we can start to return to a normal social and economic life. At some stage you are quite right to suggest that there must be a reckoning, including changes to the tax code, but it will presumably take some years before the ship is righted. It would be foolish of me to give any advice beyond saying that as far as possible keep to what you are comfortable with, do not risk investments that you cannot afford to lose. Sorry not to be more useful and good luck.
srichardson8
03/4/2020
16:41
So that shouldn't reflect on HZD one way or another. Just a tidy up operation between the other 2 companies. I wonder why HZD's share price has shot up today but I haven't checked to see whether the index has also done so. What do you think about their prospects going forward? I'm losing rather a lot on my holding and wondering whether to use the spare cash I have in my ISA to top up, or whether Next, RDSB, SMT, or Photo-Me would be a better bet. or whether none of them is worth topping up. Am losing on all but SMT and the rest of that ISA is a car crash and I wouldn't think of adding. HZD has the (very relevant to me)AIM IHT exemption at present, but for how much longer? And I wonder how long ISAs will survive. The chancellor is going to need to extract as much tax as possible.
bouleversee
03/4/2020
15:52
Danaher bought the biopharma division of GE Healthcare last year but the transaction was not completed until this past week when certain disposals were made to meet EU regulations. The cost to Danaher was reportedly $20bn. GE Healthcare had an 8.67% stake in HZD which has now transferred to Danaher. Danaher is a very large corporation with a market capitalisation of $95bn (at the current price of around $135), 20 major operating companies and most recent annual sales of $18bn. Its biggest division is medical equipment which includes Beckman Coulter a diagnostic specialist currently getting some attention as it is trying to develop a Covid-19 antibody test kit. What happens to the HZD stake is anyone's guess. Or so I understand. Corrections or amplification welcome.
srichardson8
03/4/2020
12:50
So does that mean HZD now owns those shares or have they been cancelled. Apols. for being a bit thick. Can't quite get my head round the mechanics.
bouleversee
03/4/2020
12:29
No! See my post above.
rambutan2
03/4/2020
12:23
So GE Healthcare's stake of 8.67% has been placed out according to the latest RNS?
mamcw
02/4/2020
21:43
So why the heck are they bombing?
bouleversee
02/4/2020
21:17
Many researchers and collaborators are contacting Horizon for custom RNA and other tools for #COVID19 detection assay development and #SARSCoV2 research. Take a look at the tools that we have available here:https://t.co/7n0DBlypVc
espiral59
01/4/2020
15:44
Every time someone wanted in, it also means someone else wanted out!
kestelmill
01/4/2020
15:39
gunmartin, I think those must be shares inherited from GE following HZD's acquisition of Dharmacon from GE. Sorry am a bit pushed for time... htTps://www.biopharma-reporter.com/Article/2019/06/17/GE-Healthcare-discusses-Danaher-acquisition hTtps://horizondiscoveryplc.com/financials/shareholders/
rambutan2
01/4/2020
12:47
Another big bet on HZD today (Danaher Innovation Center LLC, USA, reveal a holding of 8.67%). HZD are slap in the middle of the hottest area of biochemistry, but I'm just not sure how they are going to make money from it. I have a small holding, held for my daughter.
gnnmartin
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
ADVFN Advertorial
Your Recent History
LSE
HZD
Horizon Di..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 12:06:44